Symmetrel: Effective Antiviral and Parkinson’s Symptom Management

Symmetrel

Product dosage: 100mg
Package (num)	Per pill	Price	Buy
30	$1.57	$47.21 (0%)	🛒 Add to cart
60	$1.24	$94.42 $74.33 (21%)	🛒 Add to cart
90	$1.14	$141.63 $102.45 (28%)	🛒 Add to cart
120	$1.05	$188.84 $125.56 (34%)	🛒 Add to cart
180	$0.95	$283.26 $171.76 (39%)	🛒 Add to cart
270	$0.90	$424.88 $244.08 (43%)	🛒 Add to cart
360	$0.85 Best per pill	$566.51 $307.36 (46%)	🛒 Add to cart
Synonyms Symadine

Show more

Symmetrel (amantadine hydrochloride) is a well-established antiviral and antiparkinsonian agent with a dual therapeutic profile. As an adamantane derivative, it demonstrates efficacy in the prevention and treatment of influenza A virus infections and serves as a valuable option in managing symptoms of Parkinson’s disease and drug-induced extrapyramidal reactions. Its mechanism involves inhibition of viral uncoating and modulation of dopaminergic neurotransmission, offering clinicians a versatile tool in neurology and infectious disease contexts. Available in oral formulations, Symmetrel is recognized for its predictable pharmacokinetics and well-documented safety profile when used under appropriate medical supervision.

Features

• Active ingredient: Amantadine hydrochloride
• Available forms: 100 mg capsules and oral syrup (50 mg/5 mL)
• Mechanism: Blocks viral M2 ion channel (antiviral); enhances dopamine release and may possess anticholinergic properties (antiparkinsonian)
• Half-life: Approximately 12–18 hours in adults with normal renal function
• Excretion: Primarily renal, unchanged
• Prescription status: Rx-only in most jurisdictions

Benefits

• Reduces duration and severity of influenza A symptoms when administered early in infection
• Provides symptomatic relief in Parkinson’s disease, particularly for rigidity and bradykinesia
• Helps manage levodopa-induced dyskinesias in advanced Parkinson’s treatment
• Effective in reducing extrapyramidal symptoms induced by antipsychotic medications
• May offer neuroprotective benefits in certain contexts, though evidence is evolving
• Convenient once- or twice-daily dosing supports adherence in chronic management

Common use

Symmetrel is primarily indicated for:

• Prophylaxis and treatment of respiratory illness caused by influenza A virus strains
• Treatment of idiopathic Parkinson’s disease (Parkinsonism)
• Treatment of drug-induced extrapyramidal reactions

Its use in Parkinson’s disease may be as monotherapy in early disease or as adjunctive therapy with levodopa. In influenza, it is most effective when initiated within 48 hours of symptom onset for treatment, or prior to exposure for prophylaxis.

Dosage and direction

Dosing must be individualized based on indication, renal function, and patient tolerance.

For influenza A treatment in adults:

• 200 mg daily, either as single dose or 100 mg twice daily
• Duration: Continue for 24–48 hours after symptoms disappear (typically 3–5 days)

For influenza A prophylaxis in adults:

• 200 mg daily, or 100 mg twice daily
• Duration: Continue for at least 10 days following known exposure; up to 90 days for seasonal prophylaxis

For Parkinson’s disease:

• Initial dose: 100 mg daily
• May increase to 100 mg twice daily after one week if needed
• Some patients may benefit from 400 mg daily in divided doses, but require close monitoring

For drug-induced extrapyramidal reactions:

• 100 mg twice daily; may increase to 300 mg daily in divided doses if necessary

Dosage adjustments are required in renal impairment and elderly patients. Administration with or without food is acceptable, though taking with meals may reduce gastrointestinal upset.

Precautions

• Renal function should be assessed before and during therapy; dose adjustment necessary in impairment
• Use with caution in patients with history of seizures, as may lower seizure threshold
• May cause dizziness or blurred vision; caution patients about driving or operating machinery
• Sudden discontinuation may precipitate Parkinsonian crisis; taper gradually
• Monitor for mood changes, depression, or suicidal ideation
• Use cautiously in patients with congestive heart failure, peripheral edema, or orthostatic hypotension
• Elderly patients may be more susceptible to CNS and other adverse effects
• Not recommended during pregnancy unless potential benefit justifies potential risk
• Excreted in breast milk; decision should be made to discontinue nursing or discontinue drug

Contraindications

• Hypersensitivity to amantadine or any component of the formulation
• Severe renal impairment (creatinine clearance <15 mL/min)
• History of angle-closure glaucoma (relative contraindication)
• Concurrent use of live attenuated influenza vaccine (may reduce vaccine efficacy)

Possible side effect

Common (≥1%):

• Nausea, anorexia, constipation
• Dizziness, lightheadedness, insomnia
• Dry mouth, blurred vision
• Peripheral edema (ankle swelling)
• Livedo reticularis (mottling of skin)

Less common:

• Depression, anxiety, confusion, hallucinations
• Orthostatic hypotension
• Urinary retention
• Leukopenia, neutropenia
• Heart failure exacerbation

Rare but serious:

• Suicidal ideation
• Neuroleptic malignant syndrome (upon withdrawal)
• Seizures
• Psychotic reactions
• Severe dermatological reactions

Drug interaction

• Anticholinergic drugs: Enhanced anticholinergic effects (dry mouth, blurred vision, constipation)
• CNS stimulants: May increase nervousness, insomnia, or seizures
• Alcohol: May increase CNS effects (dizziness, confusion)
• Triamterene/hydrochlorothiazide: May reduce amantadine clearance, increasing toxicity risk
• Memantine: Theoretical increased risk of toxicity (similar mechanisms)
• Drugs affecting renal secretion (cimetidine, quinidine): May increase amantadine levels
• Levodopa: Enhanced antiparkinsonian effects, but may increase dyskinesias or psychiatric effects
• Live attenuated influenza vaccine: Symmetrel may reduce vaccine efficacy; avoid concurrent use

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. If multiple doses are missed, contact healthcare provider for guidance on resumption, as abrupt restart at full dose may increase side effect risk.

Overdose

Symptoms may include:

• Severe nausea, vomiting
• Agitation, hallucinations, aggressive behavior
• Cardiac arrhythmias, hypertension or hypotension
• Hyperthermia
• Respiratory distress
• Seizures, coma

Management:

• Supportive care is mainstay; no specific antidote exists
• Gastric lavage may be considered if presentation is early
• Activated charcoal may be administered
• Acidification of urine may enhance elimination (though controversial due to renal risk)
• Hemodialysis may be effective in severe cases with renal impairment
• Control agitation with benzodiazepines; avoid neuroleptics which may worsen symptoms
• Cardiac monitoring recommended

Storage

• Store at controlled room temperature (15–30°C or 59–86°F)
• Protect from light and moisture
• Keep bottle tightly closed
• Do not freeze oral syrup
• Keep out of reach of children and pets
• Discard any unused medication after treatment course completion; do not flush

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Symmetrel is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Dosage, indications, and precautions may vary based on individual patient factors, regional guidelines, and updated clinical evidence. Always consult with a physician or pharmacist for personalized medical advice and report any adverse effects to your healthcare provider. The manufacturer’s prescribing information should be consulted for complete details.

Reviews

Clinical studies and post-marketing surveillance demonstrate Symmetrel’s efficacy in both antiviral and neurological applications. In influenza A, it shows approximately 70-90% prophylactic efficacy against susceptible strains when initiated promptly. For Parkinson’s disease, approximately 60-70% of patients experience meaningful improvement in motor symptoms, particularly when used in combination with other antiparkinsonian agents. Many clinicians appreciate its generally favorable side effect profile compared to stronger dopaminergic agents, though most note that benefits must be weighed against potential CNS effects, especially in elderly populations. Long-term experience spanning decades supports its position as a valuable option in specific clinical scenarios.